8-KEarnings & ResultsExhibits & Filings

DEXCOM INC 8-K Report, Financial Results (Jan 9, 2023)

Filed January 9, 2023For Securities:DXCM

Summary

DexCom, Inc. (DXCM) has provided preliminary, unaudited financial results for the fourth quarter and full fiscal year 2022, along with an initial outlook for fiscal year 2023, during an investor conference. For Q4 2022, the company expects revenue to reach at least $815 million, marking a 17% increase year-over-year. Full-year 2022 revenue is projected to be approximately $2.91 billion, up over 19% from 2021, demonstrating strong top-line growth. Looking ahead to fiscal year 2023, DexCom anticipates total revenue to be in the range of $3.35 billion to $3.49 billion. These preliminary results are subject to finalization as part of the upcoming Form 10-K filing. Investors should note that these are forward-looking statements and actual results may differ due to various risks and uncertainties detailed in DexCom's SEC filings.

Key Highlights

  • 1Preliminary Q4 2022 revenue expected to be at least $815 million, a 17% increase year-over-year.
  • 2Preliminary full fiscal year 2022 revenue projected to be approximately $2.91 billion, a 19% increase over 2021.
  • 3Initial fiscal year 2023 revenue outlook is between $3.35 billion and $3.49 billion.
  • 4Results were announced during the J.P. Morgan 41st Annual Healthcare Conference on January 9, 2023.
  • 5Preliminary results are unaudited and subject to finalization in the upcoming Form 10-K.
  • 6The filing includes forward-looking statements regarding future financial performance and growth.

Frequently Asked Questions

DexCom expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2022, to be at least $815 million, representing a 17% increase compared to the fourth quarter of 2021.

For fiscal year 2023, DexCom provided an initial financial outlook anticipating total revenue to be in the approximate range of $3.35 billion to $3.49 billion.

No, the revenue figures provided are preliminary and unaudited. They are subject to finalization in connection with the preparation of DexCom's Annual Report on Form 10-K for the twelve months ended December 31, 2022.

DexCom projects its total preliminary, unaudited revenue for fiscal year 2022 to be approximately $2.91 billion, which is an increase of more than 19% over fiscal year 2021.